Note 5 - Acquisitions and Investments (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended								8 Months Ended	12 Months Ended
	May 09, 2022	Apr. 29, 2022	Jan. 31, 2023	Sep. 30, 2021	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Apr. 30, 2023
Assets					$ 2,011,698				$ 2,167,259				$ 2,167,259	$ 2,011,698	$ 2,167,259
Liabilities					622,479				605,611				605,611	622,479	605,611
Equity Method Investment, Quoted Market Value					700				1,300				1,300	700	1,300
Revenue from Contract with Customer, Excluding Assessed Tax					181,905	$ 178,595	$ 265,418	$ 237,577	185,340	$ 179,744	$ 309,893	$ 329,219		863,495	1,004,196	$ 1,774,718
LeaderMed [Member] | LeaderMed Joint Venture [Member]
Minority Interest, Shares Issued (in shares)				4,703
Subsidiary, Ownership Percentage, Parent				47.00%
Revenue from Contract with Customer, Excluding Assessed Tax				$ 1,000
Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]
Assets					85,500				167,100				167,100	85,500	167,100
Liabilities					$ 20,800				$ 46,500				$ 46,500	20,800	46,500
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest														$ 37,700	101,500
Pharmsynthez [Member]
Equity Method Investment, Ownership Percentage					8.50%									8.50%
Cocrystal Pharma, Inc. [Member]
Equity Method Investment, Ownership Percentage					2.20%									2.20%
Non-Invasive Monitoring Systems, Inc. [Member]
Equity Method Investment, Ownership Percentage					0.50%									0.50%
BioCardia [Member]
Equity Method Investment, Ownership Percentage					1.00%									1.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					47,000									47,000
Xenetic [Member]
Equity Method Investment, Ownership Percentage					2.90%									2.90%
LeaderMed [Member]
Equity Method Investment, Ownership Percentage					47.00%									47.00%
Neovasc [Member]
Equity Method Investment, Ownership Percentage					0.50%									0.50%
Proceeds from Sale of Equity Method Investments														$ 363
GeneDx Holdings [Member]
Equity Method Investment, Ownership Percentage					13.70%									13.70%
Equity Method Investment, Quoted Market Value					$ 9,800									$ 9,800
Payments to Acquire Businesses, Gross		$ 150,000
Investment Owned, Shares Purchased (in shares)			14,285,714
Payments to Acquire Equity Securities, FV-NI			$ 5,000
Stockholders' Equity, Reverse Stock Split, Conversion Per Share (in dollars per share)																	$ 33
Investment Owned, Balance, Shares (in shares)					3,558,602									3,558,602
Business Acquisition, Outstanding Shares Held, Percentage					5.00%									5.00%
Equity Securities, FV-NI, Realized Gain														$ 23,000	150,900
GeneDx Holdings [Member] | Common Class A [Member]
Business Divesture, Milestone Payment, Shares (in shares)													23,100,000
GeneDx Holdings [Member] | Maximum [Member]
Business Divesture, Milestone Payment, Shares (in shares)			30,900,000
VBI Vaccines Inc. [Member]
Equity Security, FV-NI, Ownership Percent					0.20%									0.20%
ChromaDex Corporation [Member]
Equity Method Investment, Ownership Percentage					0.05%									0.05%
Equity Security, FV-NI, Ownership Percent					0.05%									0.05%
Eloxx Pharmaceuticals, Inc. [Member]
Equity Method Investment, Ownership Percentage					1.20%									1.20%
Equity Security, FV-NI, Ownership Percent					1.20%									1.20%
CAMP4 [Member]
Equity Security, FV-NI, Ownership Percent					2.40%									2.40%
HealthSnap, Inc. [Member]
Equity Security, FV-NI, Ownership Percent					5.20%									5.20%
COCP [Member]
Equity Method Investment, Ownership Percentage					2.00%									2.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					33,000									33,000
InCellDx [Member]
Equity Method Investment, Ownership Percentage					29.00%									29.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					700,000									700,000
Zebra [Member]
Equity Method Investment, Ownership Percentage					28.50%									28.50%
Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]
Equity Method Investment, Ownership Percentage					29.00%									29.00%
Zebra [Member] | Series A-2 Preferred Stock [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]
Investment Owned, Balance, Shares (in shares)					1,260,000									1,260,000
Zebra [Member] | Restricted Stock [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]
Investment Owned, Balance, Shares (in shares)					900,000									900,000
ModeX Therapeutics, Inc [Member]
Business Combination, Consideration Transferred	$ 300,000
Business Acquisition, Share Price (in dollars per share)	$ 0.01
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	$ 221,662
Business Acquisition, Pro Forma Net Income (Loss)														$ 5,400	$ 10,600
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual														$ 51,200
Payments to Acquire Businesses, Gross	300,000
ModeX Therapeutics, Inc [Member] | Common Stock [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 219,400
Business Acquisition, Share Price (in dollars per share)	$ 2.44
ModeX Therapeutics, Inc [Member] | Fully Vested Equity Awards [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 2,300